Race Oncology (ASX:RAC) said that the Bellberry Human Research Ethics Committee approved its phase 1 trial of its reformulated bisantrene drug candidate RC220, in combination with doxorubicin for patients with solid tumors, according to a Friday filing with the Australian bourse.
The open-label, multi-center trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of the drug candidate as a standalone treatment and in combination with doxorubicin.
It will start at Southside Cancer Care Centre in New South Wales this month, pending institutional approval, with up to nine additional sites to follow, the filing said.
Stage 1 of the trial involves dose escalation to determine the maximum tolerated combined dose (MTCD) in up to 33 patients, the filing added.
Stage 2 will expand to patients who haven't received anthracyclines, confirming safety and exploring endpoints like cardioprotection and anticancer effects, the company said.
Shares of the company rose 9% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.